Skip to main content
Top
Published in: Neurological Sciences 11/2017

01-11-2017 | Original Article

Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients

Authors: Alberto Raggi, Carlo Antozzi, Fulvio Baggi, Matilde Leonardi, Lorenzo Maggi, Renato Mantegazza

Published in: Neurological Sciences | Issue 11/2017

Login to get access

Abstract

The purpose of this study is to report on the validity, reliability, and sensitivity of the myasthenia gravis activities of daily living profile (MG-ADL) in a sample of Italian patients. Patients with myasthenia gravis (MG) completed a protocol that included the MG-ADL, the WHO Disability Assessment Schedule (WHODAS 2.0), the Besta Neurological Institute rating scale for myasthenia gravis, and the MG-composite. Cronbach’s alpha was used to test reliability, Spearman’s correlation and intra-class correlation coefficient (ICC) to test short-term test-retest, Kruskal-Wallis test to assess differences in MG-ADL between patients with different disease severity, and Wilcoxon signed-rank test to assess sensitivity to change. In total, 58 patients were enrolled: 44 were females, mean MG duration 10.5 ± 10.4 years, mean MG-ADL 3.98 ± 3.07. The MG-ADL showed good internal consistency (alpha = .774), stability (test-retest correlation = .98, ICC = .97). It was superior to the WHODAS 2.0 in differentiating patients with different MG type and severity (P < .001), it showed higher sensitivity to change (P = .001 for improved and P = .007 for worsened patients) and higher correlation with the MG-composite (RHO = .625). Our analysis shows that the Italian version of the MG-ADL is valid, reliable, stable, and sensitive to change.
Literature
1.
go back to reference Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta F, Simoncini O, Campanella A, Beghi E, Cornelio F (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 998:413–423CrossRefPubMed Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta F, Simoncini O, Campanella A, Beghi E, Cornelio F (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 998:413–423CrossRefPubMed
4.
go back to reference Raggi A, Schiavolin S, Leonardi M, Antozzi C, Baggi F, Maggi L, Mantegazza R (2014) Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis. Disabil Rehabil 36:546–555CrossRefPubMed Raggi A, Schiavolin S, Leonardi M, Antozzi C, Baggi F, Maggi L, Mantegazza R (2014) Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis. Disabil Rehabil 36:546–555CrossRefPubMed
5.
go back to reference Muppidi S (2012) The myasthenia gravis—specific activities of daily living profile. Ann N Y Acad Sci 1274:114–119CrossRefPubMed Muppidi S (2012) The myasthenia gravis—specific activities of daily living profile. Ann N Y Acad Sci 1274:114–119CrossRefPubMed
6.
go back to reference Muppidi S, Wolfe GI, Conaway M, Burns TM, MG composite and MG-QOL15 study group (2011) MG-ADL: still a relevant outcome measure. Muscle Nerve 44:727–731CrossRefPubMed Muppidi S, Wolfe GI, Conaway M, Burns TM, MG composite and MG-QOL15 study group (2011) MG-ADL: still a relevant outcome measure. Muscle Nerve 44:727–731CrossRefPubMed
7.
go back to reference Cioncoloni D, Casali S, Ginanneschi F, Carone M, Veronica B, Rossi A, Giannini F (2016) Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients. Neurol Sci 37:717–723CrossRefPubMed Cioncoloni D, Casali S, Ginanneschi F, Carone M, Veronica B, Rossi A, Giannini F (2016) Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients. Neurol Sci 37:717–723CrossRefPubMed
9.
go back to reference Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400–406CrossRefPubMed Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400–406CrossRefPubMed
10.
go back to reference Antozzi C, Brenna G, Baggi F, Camera G, Maggi L, Rezzani C, Montomoli C, Mantegazza R (2016) Validation of the Besta Neurological Institute rating scale for myasthenia gravis. Muscle Nerve 53:32–37CrossRefPubMed Antozzi C, Brenna G, Baggi F, Camera G, Maggi L, Rezzani C, Montomoli C, Mantegazza R (2016) Validation of the Besta Neurological Institute rating scale for myasthenia gravis. Muscle Nerve 53:32–37CrossRefPubMed
11.
go back to reference Burns TM, Conaway M, Sanders DB, MG Composite and MG-QOL15 Study Group (2010) The MG composite: a valid and reliable tool for myasthenia gravis. Neurology 74:1434–1440CrossRefPubMedPubMedCentral Burns TM, Conaway M, Sanders DB, MG Composite and MG-QOL15 Study Group (2010) The MG composite: a valid and reliable tool for myasthenia gravis. Neurology 74:1434–1440CrossRefPubMedPubMedCentral
12.
go back to reference Garin O, Ayuso-Mateos JL, Almansa J, Nieto M, Chatterji S, Vilagut G, Alonso J, Cieza A, Svestkova O, Burger H, Racca V, Francescutti C, Vieta E, Kostanjsek N, Raggi A, Leonardi M, Ferrer M, MHADIE consortium (2010) Validation of the “World Health Organization Disability Assessment Schedule, WHODAS-2” in patients with chronic diseases. Health Qual Life Outcomes 8:51CrossRefPubMedPubMedCentral Garin O, Ayuso-Mateos JL, Almansa J, Nieto M, Chatterji S, Vilagut G, Alonso J, Cieza A, Svestkova O, Burger H, Racca V, Francescutti C, Vieta E, Kostanjsek N, Raggi A, Leonardi M, Ferrer M, MHADIE consortium (2010) Validation of the “World Health Organization Disability Assessment Schedule, WHODAS-2” in patients with chronic diseases. Health Qual Life Outcomes 8:51CrossRefPubMedPubMedCentral
13.
go back to reference Federici S, Bracalenti M, Meloni F, Luciano JV (2016) World Health Organization disability assessment schedule 2.0: an international systematic review. Disabil Rehabil 11(1):167. doi:10.1080/09638288.2016.1223177 Federici S, Bracalenti M, Meloni F, Luciano JV (2016) World Health Organization disability assessment schedule 2.0: an international systematic review. Disabil Rehabil 11(1):167. doi:10.​1080/​09638288.​2016.​1223177
14.
go back to reference Raggi A, Leonardi M, Schiavolin S, Antozzi C, Brenna G, Maggi L, Mantegazza R (2016) Validation of the MG-DIS: a disability assessment for myasthenia gravis. J Neurol 263:871–882CrossRefPubMed Raggi A, Leonardi M, Schiavolin S, Antozzi C, Brenna G, Maggi L, Mantegazza R (2016) Validation of the MG-DIS: a disability assessment for myasthenia gravis. J Neurol 263:871–882CrossRefPubMed
15.
go back to reference Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23CrossRefPubMed Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23CrossRefPubMed
16.
go back to reference Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group (2008) Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 38:1553–1562CrossRefPubMed Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group (2008) Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 38:1553–1562CrossRefPubMed
17.
go back to reference Lipka AF, Vrinten C, van Zwet EW, Schimmel KJM, Cornel MC, Kuijpers MR, Hekster YA, Weinreich SS, Verschuuren JJGM (2014) Ephedrine treatment for autoimmune myasthenia gravis. Neuromuscul Disord 27:259–265CrossRef Lipka AF, Vrinten C, van Zwet EW, Schimmel KJM, Cornel MC, Kuijpers MR, Hekster YA, Weinreich SS, Verschuuren JJGM (2014) Ephedrine treatment for autoimmune myasthenia gravis. Neuromuscul Disord 27:259–265CrossRef
18.
go back to reference Zhao CB, Zhang X, Zhang H, Hu XQ, Lu JH, Lu CZ, Xiao BG (2011) Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. Int Immunopharmacol 11:519–524CrossRefPubMed Zhao CB, Zhang X, Zhang H, Hu XQ, Lu JH, Lu CZ, Xiao BG (2011) Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. Int Immunopharmacol 11:519–524CrossRefPubMed
19.
go back to reference Tao X, Wang W, Jing F, Wang Z, Chen Y, Wei D, Huang X (2017) Long-term efficacy and side effects of low-dose tacrolimus for the treatment of myasthenia gravis. Neurol Sci 38:325–330CrossRefPubMed Tao X, Wang W, Jing F, Wang Z, Chen Y, Wei D, Huang X (2017) Long-term efficacy and side effects of low-dose tacrolimus for the treatment of myasthenia gravis. Neurol Sci 38:325–330CrossRefPubMed
Metadata
Title
Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients
Authors
Alberto Raggi
Carlo Antozzi
Fulvio Baggi
Matilde Leonardi
Lorenzo Maggi
Renato Mantegazza
Publication date
01-11-2017
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 11/2017
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-017-3083-6

Other articles of this Issue 11/2017

Neurological Sciences 11/2017 Go to the issue